SPY468.05-0.23 -0.05%
DIA357.55-0.19 -0.05%
IXIC15,668.73-18.19 -0.12%

Humanigen Announces Clinical Trial Collaboration To Evaluate Lenzilumab In Acute Graft Versus Host Disease

Humanigen is supporting the University of Birmingham to conduct a Phase 2/3, potentially registrational, clinical trial at IMPACT stem cell transplant centers across the United Kingdom The "Risk Adapted Therapy

Benzinga · 11/11/2021 06:31
  • Humanigen is supporting the University of Birmingham to conduct a Phase 2/3, potentially registrational, clinical trial at IMPACT stem cell transplant centers across the United Kingdom
  • The "Risk Adapted Therapy in Acute GvHD", or "RATinG", study is expected to begin enrolling in 1H22